Connetics’ Velac Is “Not Approvable” For Acne
This article was originally published in The Pink Sheet Daily
The only issue raised in FDA’s “not approvable” letter was a positive carcinogenicity signal found in a study involving genetically altered mice, the company says. The acne treatment combines clindamycin and tretinoin.
You may also be interested in...
Completion of the $640 million acquisition combines Stiefel’s dermatology portfolio with Connectics’ patented drug delivery technology.
Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.